Dr. Vijay Patil

Research Projects

1. Head and neck cancer
1. Patil V, Noronha V, Dhumal SB, et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health 2020;8(9):e1213–22.
2. Patil VM, Noronha V, Joshi A, et al. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. J Clin Oncol 2019;JCO1901076.
3. Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol [Internet] 2015;Available from: http://dx.doi.org/10.1016/j.oraloncology.2014.12.002
4. Joshi A, Patil VM, Noronha V, et al. Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. J Clin Orthod 2017;35(15_suppl):6018–6018.
5. Noronha V, Patil VM, Joshi A, et al. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. Oncotarget 2020;11(4):399–408.
6. Patil VM, Noronha V, Joshi A, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer [Internet] 2019;Available from: http://dx.doi.org/10.1002/cncr.32179
7. Noronha V, Joshi A, Patil VM, et al. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. J Clin Oncol 2017;JCO2017749457.
8. Patil VM, Joshi A, Noronha V, et al. Technically unresectable recurrent oral cancers: Is NACT the answer? Oral Oncol [Internet] 2016;Available from: http://dx.doi.org/10.1016/j.oraloncology.2016.03.015
9. Patil VM, Noronha V, Joshi A, et al. Neoadjuvant chemotherapy in geriatric head and neck cancers. Head Neck [Internet] 2017;Available from: http://dx.doi.org/10.1002/hed.24694
10. Patil VM, Chougule A, Noronha V, et al. DPYD Mutation in Indian Patients. Clin Oncol 2019;31(10):732–3.
11. Patil VM, Noronha V, Thiagarajan S, et al. Salvage surgery in head and neck cancer: Does it improve outcomes? Eur J Surg Oncol [Internet] 2020;Available from: http://dx.doi.org/10.1016/j.ejso.2020.01.019
12. Patil VM, Joshi A, Noronha V, et al. Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). Int J Surg Oncol 2016;2016:6923730.
13. Patil VM, Prabhash K, Noronha V, et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol 2014;50(10):1000–4.
2. Thoracic tumors
1. Patil VM, Noronha V, Joshi A, et al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open 2017;2(1):e000168.
2. Noronha V, Patil VM, Joshi A, et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol 2019;JCO1901154.
3. Patil V, Noronha V, Joshi A, et al. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. EClinicalMedicine 2019;9:19–25.
4. Patil V, Joshi A, Noronha V, et al. Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget 2019;10(59):6297–307.
5. Noronha V, Ramaswamy A, Patil VM, et al. ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. PLoS One 2016;11(9):e0160752.
6. Joshi A, Pande N, Noronha V, et al. ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. Ecancermedicalscience 2019;13:900.
7. Joshi AP, Chandrakanth MV, Noronha V, et al. Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent. Indian J Cancer 2017;54(1):144–7.
8. Noronha V, Talreja VT, Patil V, et al. Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience. South Asian J Cancer 2020;9(3):180–2.
9. Kate S, Chougule A, Joshi A, et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer 2019;10:1–10.
10. Noronha V, Choughule A, Patil VM, et al. Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. Onco Targets Ther 2017;10:2903–8.
3. Neuro-Oncology
1. Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann 2012;4(3):150–3.
2. Patil VM, Noronha V, Joshi A, et al. Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise? Urol Ann 2014;6(1):18–22.
3. Noronha V, Abraham G, Patil V, et al. A real-world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Med 2021;10(5):1525–34.
4. Ramaswamy A, Joshi A, Noronha V, et al. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. Clin Genitourin Cancer 2017;15(3):e345–55.
5. Joshi A, Ramaswamy A, Noronha V, et al. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria. Indian J Cancer 2016;53(3):423–8.
6. Zanwar S, Joshi A, Noronha V, et al. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis. Indian J Cancer 2016;53(4):579–82.
7. Joshi A, Agarwala V, Ramaswamy A, et al. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data. Indian J Cancer 2016;53(4):575–8.
8. Krishna VM, Noronha V, Prabhash K, et al. Sunitinib in metastatic renal cell carcimoma: a single-center experience. Indian J Cancer 2013;50(3):268–73.
9. Ramaswamy A, Joshi A, Noronha V, et al. Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center. Indian J Med Paediatr Oncol 2017;38(3):311–5.
10. Agarwala V, Ramaswamy A, Joshi A, et al. Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. South Asian J Cancer 2018;7(4):226–30.
11. Noronha V, Joshi A, Muddu VK, Maruti Patil V, Prabhash K. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Rep Oncol 2016;9(2):506–15.
4. Uro-Oncology
1. Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann 2012;4(3):150–3.
2. Patil VM, Noronha V, Joshi A, et al. Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise? Urol Ann 2014;6(1):18–22.
3. Noronha V, Abraham G, Patil V, et al. A real-world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Med 2021;10(5):1525–34.
4. Ramaswamy A, Joshi A, Noronha V, et al. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. Clin Genitourin Cancer 2017;15(3):e345–55.
5. Joshi A, Ramaswamy A, Noronha V, et al. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria. Indian J Cancer 2016;53(3):423–8.
6. Zanwar S, Joshi A, Noronha V, et al. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis. Indian J Cancer 2016;53(4):579–82.
7. Joshi A, Agarwala V, Ramaswamy A, et al. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data. Indian J Cancer 2016;53(4):575–8.
8. Krishna VM, Noronha V, Prabhash K, et al. Sunitinib in metastatic renal cell carcimoma: a single-center experience. Indian J Cancer 2013;50(3):268–73.
9. Ramaswamy A, Joshi A, Noronha V, et al. Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center. Indian J Med Paediatr Oncol 2017;38(3):311–5.
10. Agarwala V, Ramaswamy A, Joshi A, et al. Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. South Asian J Cancer 2018;7(4):226–30.
11. Noronha V, Joshi A, Muddu VK, Maruti Patil V, Prabhash K. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Rep Oncol 2016;9(2):506–15.
5. Gyn-Oncology
1. Dessai SB, Chakraborty S, Babu T, et al. Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. Indian J Cancer 2016;53(2):280–3.
2. Chakraborty S, Geetha M, Dessai S, Patil VM. How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients. Ecancermedicalscience 2014;8:484.
3. Dessai SB, Balasubramanian S, Patil VM, Chakraborty S, Bhattacharjee A, Vikram S. Pelvic exenteration: experience from a rural cancer center in developing world. Int J Surg Oncol 2015;2015:729658.
5. Breast cancer
1. Bajpai J, Susan D, Patil V, et al. Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India. Indian J Med Paediatr Oncol 2017;38(1):18–21.
6. Supportive Care
1. Patil V, Singhai P, Noronha V, et al. Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. J Natl Cancer Inst [Internet] 2021;Available from: http://dx.doi.org/10.1093/jnci/djab020
2. Patil VM, Chakraborty S, Bhattacharjee A, Dessai S. Survey of the State of Implementation of the American Society of Clinical Oncology/Oncology Nursing Society Safety Standards for Chemotherapy Administration in India. J Oncol Pract [Internet] 2015;Available from: http://jop.ascopubs.org/content/early/2015/08/07/JOP.2015.004481.abstract
3. Patil V, Noronha V, Joshi A, et al. Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. J Glob Oncol 2017;3(4):346–59.
4. Patil VM, Noronha V, Joshi A, et al. Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. J Oncol Pract 2017;13(6):e574–81.
5. Patil V, Noronha V, Joshi A, et al. Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach. J Glob Oncol 2018;(4):1–10.
6. Dessai SB, Chakraborty S, Sajeev Kumar PB, et al. Pilot study of single-day distress screening with the NCCN distress thermometer to evaluate the feasibility of routine distress screening in tertiary cancer center in rural India. Psychooncology [Internet] 2014;Available from: http://dx.doi.org/10.1002/pon.3739
7. Joshi A, Patil VM, Noronha V, et al. EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. South Asian J Cancer 2017;6(4):186–9.

To Top